SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dover, S. B.
Right arrow Articles by McColl, K. E. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dover, S. B.
Right arrow Articles by McColl, K. E. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Lofepramine—a safe anti-depressant in acute hepatic porphyria?

Simon B. Dover

Porphyria Research Group, Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK

Ann Graham

Porphyria Research Group, Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK

Michael R. Moore

Porphyria Research Group, Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK

Kenneth E. L. McColl

Porphyria Research Group, Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK

The acute porphyrias are a group of neuropsychiatric disorders in which a life-threatening crisis can be precipitated by a variety of drugs, including antidepressants. Because of the need to find an antidepressant that is safe for porphyria patients, we have studied the effects of lofepramine on porphyria in laboratory rats and porphyria patients. The rats did not exhibit a significant rise in hepatic {delta}-aminolaevulinic acid synthase activity (a marker of drug porphyrinogenicity) when given the drug compared with its solvent alone. Four porphyria patients exhibited no clinical evidence of disease activation after exposure to the drug. The biochemical activity of their disease was assessed by measurement of the 24-h urinary excretion of {delta}- aminolaevulinic acid and porphobilinogen (haem precursors formed prior to the metabolic block). No patient exhibited a sustained rise compared to pre-treatment levels, or between low dose and high dose lofepramine. We suggest that lofepramine is probably safe in acute porphyria, but should be used with caution.

Key Words: antidepressant • drug safety • lofepramine • porphyria

Journal of Psychopharmacology, Vol. 8, No. 2, 104-108 (1994)
DOI: 10.1177/026988119400800206
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement